A searing disappointment for patients, scientists and investors - Senior Scientist Sana Biotechnology Employee Review

Five years, and $1,000,000,000 later, they have two INDs for the same candidate, one of which was cleared nearly a year ago and has faced significant delays. This should speak for itself, but if it doesn't, consider also: Sana has missed nearly every corporate goal it has ever set by a wide margin. When it IPO'd in 2021, the company set a goal MULTIPLE clinical data readouts across two platforms within the next year or two. As of November 2023, it has yet to see any data from its singular candidate, SC291. All the while, Sana has burned through almost its entire war chest with spending habits that would make Mike Tyson look like Suze Orman. Three sites, multiple acquisitions, a manufacturing facility that's mostly for show, and an bloated bureaucracy of highly skilled, highly paid professionals whose talents are wasted by disengaged, unfocused, directionless management. Promotions, by and large, come out of a black box and are mainly given to sycophants and schmoozers whose entire purpose appears to be self-promotion, networking and navel-gazing while passing off the actual lab work to anyone else. As a result, very little has gotten done in terms of scientific progress given the massive investments Sana has made. The productive team members were largely laid off in one of the THREE rounds of layoffs over the past year, which, I stress, wouldn't have been necessary if the company had even come close to achieving the goals it outlined after its IPO. Layoffs were executed with brutal efficiency, over a zoom meeting that everyone in the company was watching, whether they were included in the layoff or not.